Therapeutic Drug Monitoring and Safety of Voriconazole Therapy in Patients with Child-Pugh Class B and C Cirrhosis: A Multicenter Study.

Taotao Wang,Miao Yan,Dan Tang,Ling Xue,Tao Zhang,Yuzhu Dong,Li Zhu,Xinggang Wang,Yalin Dong

International Journal of Infectious Diseases（2018）

引用 32|浏览25

暂无评分

摘要

•This is the first study of voriconazole pharmacokinetics and safety in cirrhosis patients.•Voriconazole Cmin for the standard dose was 6.95±3.42mg/l in cirrhosis patients.•Voriconazole Cmin was 4.02±2.00mg/l in cirrhosis patients receiving the halved dose.•Voriconazole Cmin was related to INR and CYP2C19 inhibitor use in cirrhosis patients.•Most adverse events developed within 7days after starting voriconazole treatment.

查看译文

关键词

Voriconazole,Trough concentration,Liver cirrhosis,Therapeutic drug monitoring,Adverse events

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要